5 Best Performing Healthcare ETFs in 2022

In this article, we will discuss the 5 best performing healthcare ETFs in 2022. If you want to explore similar ETFs, you can read 10 Best Performing Healthcare ETFs in 2022.

5. Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP)

YTD Return as of December 9: -2.29%

As of December 9, the Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP) has lost 2.29% year to date and has outperformed the S&P 500 by over 15%. The fund ranks among the best performing healthcare ETFs in 2022. The fund tracks the performance of the Dynamic Pharmaceutical Intellidex Index and uses a full replication technique. The fund has an expense ratio of 0.56% and pays out dividends on a quarterly basis. The fund has a yield of 0.97%.

The Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP) has 28 holdings and a top ten holdings concentration of 59.03%. Among the fund’s notable holdings, we have AbbVie Inc. (NYSE:ABBV). On November 17, Credit Suisse analyst Trung Huynh took coverage of AbbVie Inc. (NYSE:ABBV) with an Outperform rating and a $170 price target.

As of September 30, Arrowstreet Capital is the top shareholder in AbbVie inc. (NYSE:ABBV). The fund’s stakes are valued at $431.6 million in the company.

Here is what Baron Funds had to say about AbbVie Inc. (NYSE:ABBV) in its third-quarter 2022 investor letter:

“AbbVie Inc. (NYSE:ABBV) is a drug developer best known for Humira, an immunosuppressant that is the best selling drug of all time. Given outsized key product risk (patent cliff and generic launches beginning in 2023), AbbVie has broadened its pipeline, highlighted by its Allergan acquisition. Shares fell on results that missed consensus and indications that legacy franchises were outperforming newer product launches, calling into question AbbVie’s long-term strategy. With promising assets in the pipeline and its robust cash flow profile, we believe AbbVie will grow well into the future.”